Publication Information

{'id': 'https://openalex.org/W22975691', 'doi': None, 'title': 'Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.', 'display_name': 'Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.', 'publication_year': 2001, 'publication_date': '2001-10-01', 'ids': {'openalex': 'https://openalex.org/W22975691', 'mag': '22975691', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/11776281'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/11776281', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5035768670', 'display_name': 'Chen‐Hsun Ho', 'orcid': 'https://orcid.org/0000-0002-8706-7464'}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'C Ho', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5035768670'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 6, 'citation_normalized_percentile': {'value': 0.548175, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 75, 'max': 77}, 'biblio': {'volume': None, 'issue': '24', 'first_page': '1', 'last_page': '4'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10279', 'display_name': 'Urinary Bladder and Prostate Research', 'score': 0.9574, 'subfield': {'id': 'https://openalex.org/subfields/2748', 'display_name': 'Urology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10279', 'display_name': 'Urinary Bladder and Prostate Research', 'score': 0.9574, 'subfield': {'id': 'https://openalex.org/subfields/2748', 'display_name': 'Urology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/oxybutynin', 'display_name': 'Oxybutynin', 'score': 0.99708843}, {'id': 'https://openalex.org/keywords/tolterodine', 'display_name': 'Tolterodine', 'score': 0.49177578}], 'concepts': [{'id': 'https://openalex.org/C2777844464', 'wikidata': 'https://www.wikidata.org/wiki/Q1060922', 'display_name': 'Oxybutynin', 'level': 4, 'score': 0.99708843}, {'id': 'https://openalex.org/C2778941218', 'wikidata': 'https://www.wikidata.org/wiki/Q331231', 'display_name': 'Overactive bladder', 'level': 3, 'score': 0.9193824}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.76576924}, {'id': 'https://openalex.org/C205679159', 'wikidata': 'https://www.wikidata.org/wiki/Q3375179', 'display_name': 'Transdermal', 'level': 2, 'score': 0.7016372}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.51998526}, {'id': 'https://openalex.org/C2781020410', 'wikidata': 'https://www.wikidata.org/wiki/Q424312', 'display_name': 'Tolterodine', 'level': 4, 'score': 0.49177578}, {'id': 'https://openalex.org/C126894567', 'wikidata': 'https://www.wikidata.org/wiki/Q105650', 'display_name': 'Urology', 'level': 1, 'score': 0.4696117}, {'id': 'https://openalex.org/C42219234', 'wikidata': 'https://www.wikidata.org/wiki/Q131130', 'display_name': 'Anesthesia', 'level': 1, 'score': 0.39381}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.38227183}, {'id': 'https://openalex.org/C204787440', 'wikidata': 'https://www.wikidata.org/wiki/Q188504', 'display_name': 'Alternative medicine', 'level': 2, 'score': 0.0}, {'id': 'https://openalex.org/C142724271', 'wikidata': 'https://www.wikidata.org/wiki/Q7208', 'display_name': 'Pathology', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D008333', 'descriptor_name': 'Mandelic Acids', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000279', 'descriptor_name': 'Administration, Cutaneous', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002170', 'descriptor_name': 'Canada', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017322', 'descriptor_name': 'Clinical Trials, Phase II as Topic', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017326', 'descriptor_name': 'Clinical Trials, Phase III as Topic', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017277', 'descriptor_name': 'Drug Approval', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016527', 'descriptor_name': 'Drug Costs', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008333', 'descriptor_name': 'Mandelic Acids', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D008333', 'descriptor_name': 'Mandelic Acids', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D008333', 'descriptor_name': 'Mandelic Acids', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D018727', 'descriptor_name': 'Muscarinic Antagonists', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D018727', 'descriptor_name': 'Muscarinic Antagonists', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D018727', 'descriptor_name': 'Muscarinic Antagonists', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D018727', 'descriptor_name': 'Muscarinic Antagonists', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013673', 'descriptor_name': 'Technology Assessment, Biomedical', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014481', 'descriptor_name': 'United States', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014486', 'descriptor_name': 'United States Food and Drug Administration', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014549', 'descriptor_name': 'Urinary Incontinence', 'qualifier_ui': 'Q000628', 'qualifier_name': 'therapy', 'is_major_topic': False}, {'descriptor_ui': 'D014549', 'descriptor_name': 'Urinary Incontinence', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014555', 'descriptor_name': 'Urination Disorders', 'qualifier_ui': 'Q000628', 'qualifier_name': 'therapy', 'is_major_topic': False}, {'descriptor_ui': 'D014555', 'descriptor_name': 'Urination Disorders', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/11776281', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being', 'score': 0.62}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4235659438', 'https://openalex.org/W4229442422', 'https://openalex.org/W2884914054', 'https://openalex.org/W2786556341', 'https://openalex.org/W2382578058', 'https://openalex.org/W2323474658', 'https://openalex.org/W2105038172', 'https://openalex.org/W2082936610', 'https://openalex.org/W2062935753', 'https://openalex.org/W2026115116'], 'abstract_inverted_index': {'(1)': [0], 'The': [1], 'oxybutynin': [2, 13, 31, 106, 118, 136], 'patch': [3, 107, 137], 'is': [4, 71, 89, 120], 'a': [5, 33, 58], 'transdermal': [6, 28, 117], 'delivery': [7, 29], 'system,': [8], 'which': [9], 'releases': [10], 'the': [11, 15, 18, 55, 78, 99, 105, 125, 135], 'drug': [12], 'through': [14], 'skin': [16], 'for': [17, 108, 116], 'management': [19], 'of': [20, 30, 36, 62, 75, 104, 132], 'overactive': [21, 109], 'bladder.': [22, 110], '(2)': [23], 'Limited': [24], 'evidence': [25], 'suggests': [26], 'that': [27], 'over': [32], 'short': [34], 'period': [35], 'time': [37], 'may': [38], 'have': [39], 'efficacy': [40, 101], 'comparable': [41], 'to': [42, 66, 83, 97], 'oral': [43, 67], 'oxybutynin.': [44, 68], '(3)': [45], 'Recent': [46], 'phase': [47], 'II': [48], 'and': [49, 77, 102, 128], 'III': [50], 'clinical': [51], 'trials': [52], 'supported': [53], 'by': [54], 'manufacturer': [56], 'suggest': [57], 'potentially': [59], 'reduced': [60], 'incidence': [61], 'dry': [63], 'mouth': [64], 'compared': [65], 'Itching,': [69], 'however,': [70], 'present': [72], 'in': [73, 142], '18%': [74], 'patients,': [76], "patients'": [79], 'withdrawal': [80], 'rate': [81], 'due': [82], 'adverse': [84], 'events': [85], 'after': [86], '12': [87], 'weeks': [88], 'significant': [90], '(10%).': [91], '(4)': [92], 'More': [93], 'studies': [94], 'are': [95], 'required': [96], 'determine': [98], 'long-term': [100], 'safety': [103], '(5)': [111], 'A': [112], 'New': [113], 'Drug': [114, 129], 'Application': [115], '(Oxytrol(R))': [119], 'currently': [121], 'under': [122], 'review': [123], 'at': [124], 'U.S.': [126], 'Food': [127], 'Administration.': [130], 'As': [131], 'October': [133], '2001,': [134], 'has': [138], 'not': [139], 'been': [140], 'approved': [141], 'Canada.': [143]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W22975691', 'counts_by_year': [{'year': 2024, 'cited_by_count': 3}, {'year': 2023, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 1}], 'updated_date': '2024-12-13T02:28:09.622072', 'created_date': '2016-06-24'}